Tags

Type your tag names separated by a space and hit enter

Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Aliment Pharmacol Ther 2008; 28(1):2-12AP

Abstract

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome.

AIM

To assess the epidemiological impact and the current management of patients with NAFLD.

METHODS

Published peer-reviewed literature and abstracts concerning NAFLD and non-alcoholic steatohepatitis (NASH) were reviewed. Articles specifically related to epidemiology, diagnosis and current treatment strategies for NAFLD and NASH are summarized.

RESULTS

NAFLD is strongly associated with the epidemic of obesity and type-2 diabetes mellitus, and is estimated to affect about 20-30% of the population in the US. From the spectrum of NAFLD, only patients with biopsy-proven NASH (estimated prevalence in the US population is about 3-5%) have been convincingly shown to progress to cirrhosis, liver failure and hepatocellular carcinoma. The clinical manifestation of NAFLD is usually absent or subtle, with abnormal aminotransferases or incidental radiographic findings of fatty liver. The pathogenesis of NAFLD is attributed to a multi-hit process involving insulin resistance, oxidative stress, apoptotic pathways, and adipocytokines. In 2008, there is no established treatment for NAFLD. Weight loss and treatment for each component of metabolic syndrome. Nevertheless, a large number of agents are being considered in clinical trials of patients with NASH.

CONCLUSIONS

Awareness of the tremendous impact of NAFLD as an important cause of chronic liver disease is increasing along with a great deal of information about its pathogenesis. Future, well-designed clinical trials that target specific pathways involved in the pathogenesis of NASH are urgently needed.

Authors+Show Affiliations

Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA. Zobair.younossi@inova.org

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18410557

Citation

Younossi, Z M.. "Review Article: Current Management of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis." Alimentary Pharmacology & Therapeutics, vol. 28, no. 1, 2008, pp. 2-12.
Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;28(1):2-12.
Younossi, Z. M. (2008). Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics, 28(1), pp. 2-12. doi:10.1111/j.1365-2036.2008.03710.x.
Younossi ZM. Review Article: Current Management of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Aliment Pharmacol Ther. 2008;28(1):2-12. PubMed PMID: 18410557.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. A1 - Younossi,Z M, Y1 - 2008/04/11/ PY - 2008/4/16/pubmed PY - 2008/12/17/medline PY - 2008/4/16/entrez SP - 2 EP - 12 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 28 IS - 1 N2 - BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. AIM: To assess the epidemiological impact and the current management of patients with NAFLD. METHODS: Published peer-reviewed literature and abstracts concerning NAFLD and non-alcoholic steatohepatitis (NASH) were reviewed. Articles specifically related to epidemiology, diagnosis and current treatment strategies for NAFLD and NASH are summarized. RESULTS: NAFLD is strongly associated with the epidemic of obesity and type-2 diabetes mellitus, and is estimated to affect about 20-30% of the population in the US. From the spectrum of NAFLD, only patients with biopsy-proven NASH (estimated prevalence in the US population is about 3-5%) have been convincingly shown to progress to cirrhosis, liver failure and hepatocellular carcinoma. The clinical manifestation of NAFLD is usually absent or subtle, with abnormal aminotransferases or incidental radiographic findings of fatty liver. The pathogenesis of NAFLD is attributed to a multi-hit process involving insulin resistance, oxidative stress, apoptotic pathways, and adipocytokines. In 2008, there is no established treatment for NAFLD. Weight loss and treatment for each component of metabolic syndrome. Nevertheless, a large number of agents are being considered in clinical trials of patients with NASH. CONCLUSIONS: Awareness of the tremendous impact of NAFLD as an important cause of chronic liver disease is increasing along with a great deal of information about its pathogenesis. Future, well-designed clinical trials that target specific pathways involved in the pathogenesis of NASH are urgently needed. SN - 1365-2036 UR - https://www.unboundmedicine.com/medline/citation/18410557/Review_article:_current_management_of_non_alcoholic_fatty_liver_disease_and_non_alcoholic_steatohepatitis_ L2 - https://doi.org/10.1111/j.1365-2036.2008.03710.x DB - PRIME DP - Unbound Medicine ER -